| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 20 Feb 2025 | 14 Feb 2025 |
| Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/02/2025 inter alia to consider and approve of the audited financial statements for the financial year ended December 31 2024 and Recommend dividend if any for the Financial Year ended 31st December 2024. We refer to our letter dated 14th February 2025, informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that pursuant to Regulation 30 and 33 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board of Directors at its meeting held today i.e., Thursday, 20th February 2025, Approved the Audited Standalone Financial Statements of the Company for the Quarter and Financial Year ended 31st December 2024. Accordingly, we enclose a copy of the Audited Standalone Financial Statements and Auditors Report for the Financial Year ended 31st December, 2024 along with Statement of Assets and Liabilities as on that date and Standalone Statement of Cashflows for the year ended 31st December, 2024. (As Per BSE Announcement Dated on 20-02-2025) | ||
| Board Meeting | 12 Nov 2024 | 5 Nov 2024 |
| Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve the Unaudited Financial Statements (Standalone & Consolidated) for the quarter and nine months ended 30th September 2024. We refer to our letter dated 5th November 2024 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Tuesday, 12th November 2024, inter-alia considered and approved the Unaudited Financial Results for the quarter and nine months ended 30th September 2024. (As Per BSE Announcement dated on 12.11.2024) | ||
| Board Meeting | 13 Aug 2024 | 13 Sep 2024 |
| Kindly refer the enclosed file for results | ||
The company faced headwinds in the December 2024 quarter (Q4) as it reported a significant decline in earnings.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
